Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-GPRC5D (RD118) in R/R Multiple Myeloma or Plasma Cell Leukemia
NCT05219721Phase 1Recruiting
- Start
- Mar 2022
- Primary completion
- Sep 2025
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RD118 in multiple myeloma (MM) and plasma cell leukemia (PCL). Primary endpoints: Incidence of dose-limiting toxicity at 28 days and Adverse Events and Serious Adverse Events at 2 years. Started Mar 2022; status: recruiting.
02
Drugs
RD118
03
Conditions
multiple myeloma (MM)plasma cell leukemia (PCL)
Beyond the preview
Go deeper on NCT05219721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05219721.